Acknowledgements
The authors would like to acknowledge CB Marsh, W Sadee and PJ Embi, for their leadership and collaboration with both the OSUWMC-CPMC and PGRN Translational Pharmacogenomics Project projects.
Financial & competing interests disclosure
This work was supported in part by the grant U01 GM92655 and a subaward for the Translational Pharmacogenomics Project via U01 HL105198 ‘Pharmacogenomics of anti-platelet intervention-2 (PAPI-2)‘ from NHLBI. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.